November 10 is World NET Cancer Day: Spreading Rare Disease Awareness
source: shutterstock.com

November 10 is World NET Cancer Day: Spreading Rare Disease Awareness

November 10 is recognized as World Neuroendocrine Tumor (NET) Cancer Day, a time to spread awareness about neuroendocrine tumors, a group of rare cancers, among the medical field and in…

Continue Reading November 10 is World NET Cancer Day: Spreading Rare Disease Awareness
Compassion Corner: A Patient Almost Died Because of a Doctor’s Lack of Understanding and Compassion
source: pixabay.com

Compassion Corner: A Patient Almost Died Because of a Doctor’s Lack of Understanding and Compassion

  Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is…

Continue Reading Compassion Corner: A Patient Almost Died Because of a Doctor’s Lack of Understanding and Compassion
Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
https://unsplash.com/photos/_jbClosDsD4

Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors

The National Medical Products Administration (NMPA) of China has recently approved surufatinib for drug registration for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). HUTCHMED Limited recently announced the news,…

Continue Reading Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose
source: pixabay.com

Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose

According to a story from businesswire.com, the biopharmaceutical company Ipsen recently presented a total of 9 study abstracts at the recent 18th annual conference of the European Neuroendocrine Tumor Society…

Continue Reading Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose
Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
bdyczewski / Pixabay

Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical…

Continue Reading Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

New Treatment for GEP-NETs Approved in Canada

According to a story from pm360online.com, the Novartis company Advanced Accelerator Applications S.A. recently announced that Health Canada has issued approval for Lutathera™ as a treatment for gasteroenteropancreatic neuroendocrine tumors…

Continue Reading New Treatment for GEP-NETs Approved in Canada

Press Release: ASCO Names Advance of the Year: Progress in Treating Rare Cancers

Progress Report Debuts ASCO’s Research Priorities for the Cancer Community, Emphasizes Impact of Federal Funding FOR IMMEDIATE RELEASE January 31, 2019 Ashley Yum 571-483-1376 [email protected]   ALEXANDRIA, Va. — Over the…

Continue Reading Press Release: ASCO Names Advance of the Year: Progress in Treating Rare Cancers